Cholesterol inhibits aspirin
This article was originally published in The Tan Sheet
Patients with higher mean concentrations of total and LDL cholesterol showed poorer response to aspirin therapy than patients with lower cholesterol levels, according to study published in Jan. 11 British Medical Journal. Maribeth Friend, et al., University of Maryland Medical Center, sought to determine "impact of hypercholesterolemia on platelet responsiveness in patients treated with aspirin." Study enrolled 56 recruits from school's Preventive Cardiology Outpatient Center; 14 patients with poor responsiveness to aspirin had "significantly higher" concentrations of total, LDL cholesterol than the 42 patients with good responsiveness, researchers find...
You may also be interested in...
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.